Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival), at the ESMO 2012 (European Society for Medical Oncology) Congress in Vienna, Austria on October 1, 2012. In addition, nonclinical data on PV-10 will be presented at the Society for Immunotherapy of Cancer Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. Craig Dees, PhD, CEO of Provectus, will present nonclinical PV-10 data that have been included in Abstract #1452582, in a poster presentation (Poster #169) entitled "Generation of an antitumor response and immunity using a small molecule drug (PV-10)." PV-10 is Provectus Pharmaceuticals's novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects.